WCG IPO Presentation Deck
WCG and CROS - Complementary Business Models - We Support The Entire CRO
Industry: Including 8 of the Top 8
CRO Business Model
Client Engagement: Trial-by-Trial Bookings & Execution
Business Model: Staffing-Centric
Highly Competitive Environment Among CROS
Dependent on Third Parties for Specialized Technology & Science
Ad hoc Site & Patient Relationships: Trial-by-Trial
High Employee Turnover
Mature Business Models Growing in line with R&D Spending
EBITDA Margins: -15-25%
Revenue Growth: -8-10%
32
wcg
WCG Business Model
Client Engagement: Sustained Platform Connecting All Clinical Trial
Stakeholders
Business Model: Technology-centric with Data-driven Insights
Unique Integrated Solutions Without Direct Competition
Adj. EBITDA Margins: -45%
A Leading Provider of Specialized Technology & Science to CROS
Institutionalized Contractual Relationships with Sites & Patient Advocacy
Groups
Commitment to Mission & Social Responsibility Leads to High Employee
Retention
Differentiated Growth Profile Driven by Purpose-Built Solutions
Expected Long Term Revenue CAGR: 20-25%
DN L
wcg™
(1) Long-term growth expectations are the Company's goals based on third-party TAM growth projections and should not be viewed as a
guarantee of future performance or guidance for any period. Actual results may differ, and such differences may be material..View entire presentation